RxDoctor Payments DataLook up a doctor →

Bradford Whitmer, DO

Gastroenterology · Saint Clair Shores, MINPI 1669636965

Payments from drug & device makers

$205,971in general payments, 2019–2025

Across 609 payments — averaging $338.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$86K
  • Aimmune Therapeutics, Inc.$49K
  • Nestle Healthcare Nutrition Inc.$26K
  • Sanofi$20K
  • E.r. Squibb & Sons, L.L.C.$17K
  • Bristol Myers Squibb$3K
  • plus $5K from 23 others

What the payments were for

  • Consulting fees$7,0193%
  • Speaking & faculty fees$176,65586%
  • Travel & lodging$10,0075%
  • Food & beverage$12,1866%
  • Education$1040%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$205,971 in reported general payments places this provider in the 90th percentile of 497 gastroenterology providers in Michigan.

See all gastroenterology providers in Michigan

Medicare billing

Part B allowed, 2024
$109,405
Medicare patients
377
Services billed
1,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab47$1,277,176
Humira(Cf) PenAdalimumab25$167,988
CreonLipase/Protease/Amylase31$98,563
ZenpepLipase/Protease/Amylase16$87,766
XeljanzTofacitinib Citrate13$72,217
Mesalamine40$37,223
OzempicSemaglutide18$24,803
MotegrityPrucalopride Succinate24$20,903
LinzessLinaclotide18$17,406
Dexlansoprazole DrDexlansoprazole18$7,579
Budesonide EcBudesonide25$6,816
TrulancePlecanatide13$6,770
Colesevelam Hcl39$3,987
Balsalazide Disodium22$3,979
Budesonide DrBudesonide35$3,762

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,039$1,277,17647 claims
AbbVieCreon, Linzess$85,875$115,96949 claims
Aimmune Therapeutics, Inc.Zenpep$49,329$87,76616 claims
PfizerXeljanz$615$72,21713 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$506$20,90324 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$275$6,77013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 497 gastroenterology providers in Michigan.

Other gastroenterology in Saint Clair Shores

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →